

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

BODISEN BIOTECH, INC
Form 10QSB
May 16, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2004

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 333-99101

BODISEN BIOTECH, INC.

(Name of small business issuer in its charter)

Delaware

98-0381367

(State or other jurisdiction
of incorporation)

(IRS Employer Identification No.)

North Part of Xinquia Road, Yang Ling Agricultural High-Tech Industries
Demonstration Zone, Yang Ling, People's Republic of China 712100

(Address of principal executive offices)

86-29-87074957

(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act, during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 15,268,000 shares of common stock, par value \$.0001 per share

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

Table of Contents

Part I. Financial Information

Item 1 Financial Statements (Unaudited):

Consolidated Statements of Income
for the Three Months Ended March 31, 2005 and 2004.....

Consolidated Balance Sheet
for the Three Months Ended March 31, 2005 and 2004.....

Consolidated Statement of Cash Flows
as of March 31, 2005 and December 31, 2004.....

Notes to Condensed Consolidated Financial Statements.....

Item 2 Management's Discussion and Analysis or Plan of Operation.....

Item 3 Controls and Procedures.....

Part II. Other Information

Item 6 Exhibits and Reports on Form 8-K.....

Signatures.....

Exhibit Index.....

PART I. FINANCIAL INFORMATION

Item I. Financial Statements

BODISEN BIOTECH, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

	March 31, 2005
Net revenue	\$ 4,701,675
Cost of revenue	3,047,498
	1,654,178
Gross profit	
Operating expenses	
Selling expenses	148,140

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

General and administrative expenses	278,470
<hr style="border-top: 1px dashed black;"/>	
Total operating expenses	426,610
Income from operations	1,227,567
Non-operating Income (expense):	
Finance charge	(416,703)
Interest expense	(14,132)
<hr style="border-top: 1px dashed black;"/>	
Total non-operating income (expense)	(430,835)
<hr style="border-top: 1px dashed black;"/>	
Income before income tax	796,733
Provision for income tax	
<hr style="border-top: 1px dashed black;"/>	
Net Income	796,733
OTHER COMPREHENSIVE INCOME (LOSS)	
Foreign currency translation gain	-
<hr style="border-top: 1px dashed black;"/>	
COMPREHENSIVE INCOME	\$ 796,733
<hr style="border-top: 3px double black;"/>	
Basic weighted average shares outstanding	15,268,000
Basic earnings per share	0.05
Diluted weighted average shares outstanding	15,529,458
Diluted earnings per share	0.05

The accompanying notes are an integral part of these consolidated financial statements.

3

BODISEN BIOTECH, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (Unaudited)

	AS OF MARCH 31, 2005
<hr style="border-top: 1px dashed black;"/>	
ASSETS	
CURRENT ASSETS:	
Cash & cash equivalents	\$ 2,793,132
Accounts receivable, net	7,881,837
Advances to Suppliers	600,073
Inventory	967,597
Other Assets	600,443
<hr style="border-top: 1px dashed black;"/>	
Total current assets	\$ 12,843,081
PROPERTY AND EQUIPMENT, NET	3,384,620
CAPITAL WORK IN PROGRESS	410,977
INTANGIBLE ASSETS, NET	2,167,169
<hr style="border-top: 1px dashed black;"/>	
TOTAL ASSETS	\$ 18,805,847
<hr style="border-top: 3px double black;"/>	
LIABILITIES AND STOCKHOLDERS' EQUITY	
CURRENT LIABILITIES:	

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

Accounts payable	286,958
Accrued expenses	279,677
Short term loan	968,000
Convertible debenture, net discount due to beneficial conversion	2,542,723
Total current liabilities	\$ 4,077,358
LONG TERM LIABILITIES:	
Long term loans	12,100
STOCKHOLDERS' EQUITY	
Preferred stock, \$0.0001 per share; authorized 5,000,000 shares; none issued	-
Common stock, \$0.0001 per share; authorized 30,000,000 shares; issued and outstanding 15,268,000 shares	1,527
Additional paid in capital	6,885,401
Accumulated other comprehensive gain	68,855
Statutory reserve	1,137,415
Retained earnings	6,623,192
Total stockholders' equity	14,716,389
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 18,805,847

The accompanying notes are an integral part of these consolidated financial statements.

4

BODISEN BIOTECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

	FOR THE THR
	MARCH 31, 2005
CASH FLOWS FROM OPERATING ACTIVITIES:	
Net Income	\$ 796,733
Adjustments to reconcile net income to net cash used in operating activities:	
Depreciation and amortization	77,509
(Increase) / decrease in current assets:	
Accounts receivable	(2,892,853)
Advances to suppliers	155,137
Inventory	(200,253)
Other assets	(551,707)
Increase / (decrease) in current liabilities:	
Accounts payable	174,614
Unearned revenue	0
Other payables	0
Accrued expenses	34,772
Net cash used in operating activities	(2,406,047)
Effect of exchange rate on cash	

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

CASH FLOWS FROM INVESTING ACTIVITIES	
Acquisition of property & equipment	(890,633)
Work in Progress	-
Net cash used in investing activities	(890,633)
CASH FLOWS FROM FINANCING ACTIVITIES:	
Proceeds from Convertible Debt	3,000,000
Loans receivable	968,000
Net cash provided by financing activities	3,968,000
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS	
	671,320
CASH & CASH EQUIVALENTS, BEGINNING BALANCE	2,121,811
CASH & CASH EQUIVALENTS, ENDING BALANCE	\$ 2,793,132

The accompanying notes are an integral part of these consolidated financial statements.

5

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2005
(Unaudited)

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Yang Ling Bodisen Biology Science and Technology Development Company Limited ("BBST") was founded in the People's Republic of China on August 31, 2001. BBST, located in Yang Ling Agricultural High-Tech Industries Demonstration Zone, is primarily engaged in developing, manufacturing and selling pesticides and compound organic fertilizers in the People's Republic of China. Bodisen International, Inc. ("BII"), a Delaware Corporation, was incorporated on November 19, 2003. BII was a non-operative holding company of BBST. On December 15, 2003, BII entered in to an agreement with all the shareholders of BBST to exchange all of the outstanding stock of BII for all the issued and outstanding stock of BBST. After the consummation of the agreement, the former shareholders of BBST owned 1500 shares of common stock of BII, which represented 100% of BII's issued and outstanding shares. For U.S. Federal income tax purpose, the transaction was intended to be qualified as a tax-free transaction under section 351 of the Internal Revenue Code of 1986, as amended.

The exchange of shares with BBST has been accounted for as a reverse acquisition under the purchase method of accounting since the shareholders of the BBST obtained control of the consolidated entity. Accordingly, the merger of the two companies has been recorded as a recapitalization of BBST, with BBST being treated as the continuing entity. The historical financial statements presented are those of BBST. The continuing company has retained December 31 as its fiscal year end. The financial statements of the legal acquirer are not significant; therefore, no pro forma financial information is submitted.

On February 24, 2004, BII consummated a merger agreement with Stratabid.com, Inc. ("Stratabid"), a Delaware corporation, to exchange 12,000,000 shares of Stratabid to the shareholders of BII, in which BII merged into Bodisen Holdings, Inc. ("BHI"), an acquisition subsidiary of Stratabid, with BHI being the surviving entity. As a part of the merger, Stratabid cancelled 3,000,000 shares

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

of its issued and outstanding stock owned by its former president and declared a stock dividend of three shares for each share of its common stock outstanding for all stockholders of record as of February 27, 2004.

Stratabid was incorporated in the State of Delaware on January 14, 2000 and before the merger, was a start-up stage Internet based commercial mortgage origination business based in Vancouver, BC, Canada. The exchange of shares with Stratabid has been accounted for as a reverse acquisition under the purchase method of accounting since the shareholders of BII obtained control of Stratabid. On March 1, 2004, Stratabid was renamed Bodisen Biotech, Inc. (the "Company"). Accordingly, the merger of the two companies has been recorded as a recapitalization of the Company, with the Company being treated as the continuing entity. The financial statements of the legal acquiree are not significant; therefore, no pro forma financial information is submitted.

6

BODISEN BIOTECH, INC. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS March 31, 2005 (Unaudited)

2. BASIS OF PRESENTATION

The accompanying unaudited financial statements of the Company have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all of the information required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the interim periods are not necessarily indicative of the results for any future period. These statements should be read in conjunction with the Company's audited financial statements and notes thereto for the fiscal year ended December 31, 2004.

Accounts receivable

The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. Terms of the sales vary from COD through a credit term up to 9 to 12 months. Reserves are recorded primarily on a specific identification basis. Allowance for doubtful debts amounted to \$216,395 at March 31, 2005. Advances to suppliers The Company advances to certain vendors for purchase of its material. The advances to suppliers are interest free and unsecured. The advances amounted to \$600,073 at March 31, 2005.

Income taxes

The Company utilizes Statement of Financial Accounting Standard ("SFAS") No. 109, "Accounting for Income Taxes," which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. According to the Provisional Regulations of the People's Republic of China on

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

Income Tax, the Document of Reductions and Exemptions of Income Tax for the Company had been approved by the local tax bureau and the Yang Ling Agricultural

High-Tech Industries Demonstration Zone. The Company is exempted from income tax through March 31, 2005.

Fair value of financial instruments

7

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2005
(Unaudited)

SFAS No. 107, "Disclosures About Fair Value of Financial Instruments", requires the Company to disclose estimated fair values of financial instruments. The carrying amounts reported in the statements of financial position for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.

Foreign currency transactions and comprehensive income (loss) Accounting principles generally require that recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company is the Chinese Renminbi. The unit of Renminbi is in Yuan. Translation gains are classified as an item of other comprehensive income in the stockholders' equity section of the consolidated balance sheet. During the three month period ended March 31, 2005 comprehensive income in the consolidated statements of operation included no translation gain and in the three month period of March 31, 2004 the consolidated statements of operation included translation gains of \$40,575. Segment reporting The Company consists of one reportable business segment. All revenue is from customers in People's Republic of China. All of the Company's assets are located in People's Republic of China.

Recent Pronouncements

On May 15 2003, the Financial Accounting Standards Board ("FASB"), issued FASB Statement No. 150 ("SFAS 150"), Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity. SFAS 150 changes the accounting for certain financial instruments that, under previous guidance, could be classified as equity or "mezzanine" equity, by now requiring those instruments to be classified as liabilities (or assets in some circumstances) in the statement of financial position. Further, SFAS 150 requires disclosure regarding the terms of those instruments and settlement alternatives. SFAS 150 affects an entity's classification of the following freestanding instruments: (a) Mandatorily redeemable instruments (b) Financial instruments to repurchase an entity's own equity instruments, (c) Financial instruments embodying obligations that the issuer must or could choose to settle by issuing a variable number of its shares or other equity instruments based solely on (i) a fixed monetary amount known at inception or (ii) something other than changes in its own equity instruments and (d) SFAS 150 does not apply to features embedded in a financial instrument that is not a derivative in its entirety. The guidance in SFAS 150 is generally effective for all financial instruments entered into or modified after May 31, 2003, and is otherwise effective at the beginning of the

8

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2005
(Unaudited)

first interim period beginning after June 15, 2003. For private companies, mandatorily redeemable financial instruments are subject to the provisions of SFAS 150 for the fiscal period beginning after December 15, 2003. The Company does not expect the adoption of SFAS No. 150 to have a material impact on its financial position or results of operations or cash flows.

In December 2003, the FASB issued a revised Interpretation No. 46, "Consolidation of Variable Interest Entities" (FIN 46R). FIN 46R addresses consolidation by business enterprises of variable interest entities and significantly changes the consolidation application of consolidation policies to variable interest entities and, thus improves comparability between enterprises engaged in similar activities when those activities are conducted through variable interest entities. The Company does not hold any variable interest entities.

3. PRINCIPLES OF CONSOLIDATION

The accompanying consolidated financial statements include the accounts of Bodisen Biotech, Inc. (from the merger date), its 100% wholly-owned subsidiary "BHI" and BHI's 100% wholly-owned subsidiary Yang Ling Bodisen Biology Science and Technology Development Company Limited. All significant inter-company accounts and transactions have been eliminated in consolidation.

4. MAJOR VENDORS

Five vendors provided 85% of the Company's raw materials for the three month period ended March 31, 2005 and two vendors provided 42% of the Company's raw materials for the three month period ended March 31, 2004. The payable balance for these parties amounted to \$197,648 and \$3,560 at March 31, 2005 and 2004, respectively.

5. INTANGIBLE ASSETS

Net intangible assets at March 31, 2005 were as follows:

Rights to use land	\$	1,666,920
Fertilizers proprietary technology rights		968,000

	\$	2,634,920
Less Accumulated amortization		(467,751)

	\$	2,167,169

The Company's office and manufacturing site is located in the Yang Ling Agricultural High-Tech Industries Demonstration Zone in the province of Shaanxi, People's Republic of China. The Company leases land per a real estate contract with the government of People's Republic of China for a period from November 2001 through November 2051. As set forth in the People's Republic of China's governmental regulations, the Government owns all land.

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

March 31, 2005
(Unaudited)

During July 2003, the Company leased another parcel of land under a real estate contract with the government of the People's Republic of China for a period from July 2003 through June 2053.

The Company recognizes the amounts paid for the acquisition of the "Rights to Use Land" as intangible assets and amortizes them over a period of fifty (50) years.

The Company acquired Fluid and Compound Fertilizers proprietary technology rights with a life ending December 31, 2011. The Company is amortizing Fertilizers proprietary technology rights over a period of ten years.

Amortization expense for the Company's intangible assets for the three month period ending March 31, 2005 and 2004 amounted to \$32,470 each period.

Amortization expense for the Company's intangible assets over the next five fiscal years is estimated to be: 2005-\$130,000, 2006-\$130,000, 2007-\$130,000, 2008-\$130,000 and 2009-\$100,000.

6. SHAREHOLDERS' EQUITY

On February 24, 2004, BII entered into a merger agreement with Stratabid to exchange 12,000,000 shares of Stratabid to the shareholders of BII (note 12). As a part of the merger, Stratabid cancelled 3,000,000 shares of its issued and outstanding stock owned by a majority shareholder and declared a stock dividend of three shares for each share of its common stock outstanding for all stockholders of record as of February 27, 2004. The Company has a total of 15,268,000 shares of common stock outstanding as of March 31, 2005.

7. CONVERTIBLE DEBENTURE

On March 16, 2005, the Company completed a private placement offering. The Company received the sum of \$3 million and issued a one year 9% debenture convertible into shares of common stock by dividing the aggregate principal and accrued interest by a conversion price of \$4.80; a three year warrant to purchase 187,500 shares of common stock at \$4.80 per share; and a three year warrant to purchase 40,000 shares of common stock at \$6.88 per share.

This debenture was considered to have an embedded beneficial conversion feature because the conversion price was less than the quoted market price at the time of the issuance. Accordingly, the beneficial conversion feature was valued separately and the intrinsic value in the amount of \$476,875 was recorded as an increase to additional pay-in capital and a corresponding amount, less the amortized interest costs of \$19,598, was recorded as a reduction of the carrying value of the convertible debenture.

In connection with the convertible debenture, the Company issued a three year warrant to purchase 187,500 shares of common stock at \$4.80 per share and a three year warrant to purchase 40,000 shares of common stock at \$6.88 per share. The aggregate fair value of the warrants of \$416,703 was charged against net income

10

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2005
(Unaudited)

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

in the 3-month period ending March 31, 2005 and a corresponding amount was recorded as an increase to additional pay-in capital.

8. STOCK OPTIONS AND WARRANTS

In December 2002, the FASB issued SFAS No. 148 "Accounting for Stock Based Compensation-Transition and Disclosure". SFAS No. 148 amends SFAS No. 123, "Accounting for Stock Based Compensation", to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this Statement amends the disclosure requirements of Statement 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used, on reported results. The Statement is effective for the Companies' interim reporting period ending January 31, 2003.

In compliance with SFAS No. 148, the Company has elected to continue to follow the intrinsic value method in accounting for its stock-based employee compensation plan as defined by APB No. 25 and has made the applicable disclosures below.

Had the Company determined employee stock based compensation cost based on a fair value model at the grant date for its stock options under SFAS 123, the Company's net earnings per share would have been adjusted to the pro forma amounts for the three month period ended March 31, 2005 as follows: (\$ in thousands, except per share amounts)

	Three month period ended March 31, 2005	Three Ma
Net Income - as reported	\$840	
Stock-Based employee compensation expense included in reported net income, net of tax		
Total stock-based employee compensation under fair-value-based method for all rewards, net of tax	(12)	
Pro forma net income	\$828	

Earnings per share:

	Three month period ended March 31, 2005	Three month per March 31, 2
Basic, as reported	\$0.05	\$0.03
Diluted, as reported	\$0.05	\$0.03
Basic, pro forma	\$0.05	\$0.03
Diluted, pro forma	\$0.05	\$0.03

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

11

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2005
(Unaudited)

In 2004 the board of directors approved the creation of the 2004 Stock Option Plan. This plan provides for the grant of incentive stock options to employees, directors and consultants. Options issued under this plan will expire over a maximum term of five years from the date of grant.

Pursuant to the Stock Option Plan, the Company granted 110,000 stock options to two Directors (55,000 options each) during the year ended December 31, 2004, of which 100,000 stock options were granted on June 4, 2004 and the balance of the 10,000 were granted on Dec. 28, 2004.

On the first 100,000 stock options granted, 50,000 stock options vested immediately and 50,000 stock options became vested over 8 equal quarterly installments, with the first installment vesting at the end of the second quarter of 2004. The 10,000 stock options granted on Dec. 28, 2004 vested on Dec. 31, 2004.

The option exercise price was \$5 for the first 100,000 stock options which was equal to the market price of the shares at the time the options were granted. The option exercise price was \$5.80 for the second 10,000 stock options which was the market price of the shares at the time the options were granted.

The Company did not grant any option during the three month period ended March 31, 2005.

On March 16, 2005, in connection to the convertible debenture the Company issued three year warrants to purchase 187,500 shares of common stock at \$4.80 per share and three year warrants to purchase 40,000 shares of common stock at \$6.88 per share.

As of March 31, 2005, there were a total of 110,000 stock options granted and outstanding, and there were no stock options issued and outstanding as of March 31, 2004. As of March 31, 2005, there were a total of 227,000 warrants issued and outstanding, and there were no warrants issued and outstanding as of March 31, 2004.

9. SUPPLEMENTAL DISCLOSURE OF CASH FLOWS

The Company prepares its statements of cash flows using the indirect method as defined under the SFAS No. 95. Accordingly, the Company paid \$37,794 and \$27,415 for interest and \$0 and \$0 for income tax during the three month period ended March 31, 2005 and 2004, respectively.

10. STATUTORY COMMON WELFARE FUND AND RESERVE

As stipulated by the Company Law of the People's Republic of China, net income after taxation can only be distributed as dividends after appropriation has been made for the following:

- (i) Making up cumulative prior years' losses, if any;
- (ii) Allocations to the "Statutory surplus reserve" of at least 10% of income after tax, as determined under PRC accounting rules and

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

regulations, until the fund amounts to 50% of the Company's registered capital;

- (iii) Allocations of 5-10% of income after tax, as determined under People's Republic of China accounting rules and regulations, to the Company's "Statutory common welfare fund", which is established for the purpose of providing employee facilities and other collective benefits to the Company's employees; and
- (iv) Allocations to the discretionary surplus reserve, if approved in the shareholders' general meeting.

12

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2005
(Unaudited)

In accordance with the Chinese Company Law, the company has allocated 10% of its annual net income, amounting \$79,673 and \$42,097 as statutory reserves for the three month period ended March 31, 2005 and 2004, respectively.

The Company makes annual contributions of 14% of all employees' salaries to employee welfare plan. The total expense for the above plan \$20,502 and \$14,669 for the three month period ended March 31, 2005 and 2004, respectively.

11. FACTORY LOCATION AND LEASE COMMITMENTS

Our principal executive offices are located at North Part of Xinquia Road, Yang Ling Agricultural High-Tech Industries Demonstration Zone Yang Ling, Shaanxi province, People's Republic of China, 712100. We own two factories, which include three production lines, an office building, one warehouse, and two research labs which are located on 10,900 square meters of land. The rent of the office building is \$121 a month from May 20, 2004 through May 20, 2005. We also lease a warehouse in Yang Ling near the site of our factories. This warehouse is 300 square meters in area. The rent of the warehouse is \$194 a month from January 2005 through May 2005. We completed a new 609,840 square foot manufacturing facility on March 15, 2005 and we believe that our owned and leased property is sufficient for our current and immediately foreseeable operating needs. Total future commitments through June 30, 2005 amount to \$1,276.

12. EARNINGS PER SHARE

Earnings per share for the three month periods ended March 31, 2005 and 2004 were determined by dividing net income for the periods by the weighted average number of both basic and diluted shares of common stock and common stock equivalents outstanding.

The following is an analysis of the differences between basic and diluted earnings per common share in accordance with SFAS No. 128, "Earnings Per Share".

	Three month period ended March 31, 2005	Three m Ma
-----	-----	-----
Weighted average common shares outstanding	15,268,000	

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

Effect of dilutive securities: stock options	261,458
Weighted average common shares outstanding and common share equivalents	15,529,458

13

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2005
(Unaudited)

13. MERGER AGREEMENT

On February 11, 2004, Stratabid entered into an Agreement and Plan of Merger with BHI, a wholly-owned subsidiary of Stratabid, BII and the shareholders of BII. BII has one 100% wholly-owned subsidiary in Shaanxi, China, BBST. Under the terms of the agreement, BHI acquired 100 percent of BII's stock in exchange for the issuance by Stratabid of three million shares of its common stock to the holders of BII. The new shares constitute approximately 79 percent of the outstanding shares of Stratabid, which changed its name to Bodisen Biotech, Inc. (the "Company"). The Agreement and Plan of Merger was closed on February 24, 2004.

BII's Chairman of the Board was appointed the Company's Chief Executive Officer.

At the Effective Time, by virtue of the Merger and without any action on the part of the BHI, BII or the BII Shareholders, the shares of capital stock of each of BII and the BHI were converted as follows:

(a) Capital Stock of the BHI. Each issued and outstanding share of the BHI's capital stock continued to be issued and outstanding and was converted into one share of validly issued, fully paid, and non-assessable common stock of the surviving company. Each stock certificate of the BHI evidencing ownership of any such shares continued to evidence ownership of such shares of capital stock of the Surviving Company.

(b) Conversion of BII Shares. Each BII Share that was issued and outstanding at the Effective Time was automatically cancelled and extinguished and converted, without any action on the part of the holder thereof, into the right to receive at the time and in the amounts described in the Agreement an amount of Acquisition Shares equal to the number of Acquisition Shares divided by the number of BII Shares outstanding immediately prior to Closing. All such BII Shares, so converted, were no longer outstanding and were automatically cancelled and retired and ceased to exist, and each holder of a certificate representing any such shares ceased to have any rights with respect thereto, except the right to receive the Acquisition Shares paid in consideration therefore upon the surrender of such certificate in accordance with the Agreement.

(c) Within thirty (30) days from the Closing Date, Stratabid was required to sell its business operations, as they exist immediately prior to the Closing, to Derek Wasson, former president. In consideration of the sale, Mr. Wasson returned 750,000 Common Shares to Stratabid for cancellation. In addition, Mr. Wasson forgave all indebtedness owed by Stratabid to Mr. Wasson. Other than indebtedness of BII, Stratabid had no indebtedness or other liability of any kind or nature after the sale of the business to Mr. Wasson, save and except for liabilities incurred in connection with the Merger.

14. CURRENT VULNERABILITY DUE TO CERTAIN CONCENTRATIONS

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

The Company's operations are carried out in the People's Republic of China. Accordingly, the Company's business, financial condition and results of operations may be influenced by the political, economic and legal environments in China and by the general state of China's economy. The Company's business may be influenced by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

15. RECLASSIFICATIONS

Certain prior period amounts have been reclassified to conform to the period ended March 31, 2005 presentation.

14

BODISEN BIOTECH, INC.

Management's Discussion and Analysis or Plan of Operation

Item 2. Management's Discussion and Analysis or Plan of Operation

INFORMATION REGARDING FORWARD LOOKING STATEMENTS

The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto set forth in Item 1 of this Quarterly Report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions, which could cause actual results to differ materially from Management's expectations. Factors that could cause differences include, but are not limited to, expected market demand for the Company's services, fluctuations in pricing for products distributed by the Company and services offered by competitors, as well as general conditions of the agricultural products marketplace.

Some of the information in this Form 10-QSB contains forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as "may," "will," "expect," "anticipate," "believe," "estimate" and "continue," or similar words. You should read statements that contain these words carefully because they:

- o discuss our future expectations;
- o contain projections of our future results of operations or of our financial condition; and
- o state other "forward-looking" information.

We believe it is important to communicate our expectations. However, there may be events in the future that we are not able to accurately predict or over which we have no control. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth in our filings with the Securities and Exchange Commission.

Overview

We are incorporated under the laws of the state of Delaware and are headquartered in the Shaanxi Province, People's Republic of China. We engage in the business of manufacturing and marketing a brand of organic fertilizers in China. We produce numerous proprietary product lines, from pesticides to crop specific fertilizer. These products are then marketed and sold to farmers

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

throughout the 20 provinces of China. We conduct research and development to further improve existing products and develop new formulas and products.

Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

15

BODISEN BIOTECH, INC. Management's Discussion and Analysis or Plan of Operation

Accounts Receivable

We maintain reserves for potential credit losses on accounts receivable. We review the composition of accounts receivable and analyze historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. Reserves are recorded primarily on a specific identification basis.

Inventories

Inventories are valued at the lower of cost (determined on a weighted average basis) or market. We compare the cost of inventories with the market value and allowance is made for writing down the inventories to their market value, if lower.

Property & Equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.

Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives of: 30 years for building, 10 years for machinery, 5 years for office equipment and 8 years for vehicles.

Intangible Assets

Intangible assets consist of rights to use land and proprietary technology rights to fertilizers. We evaluate intangible assets for impairment, at least on an annual basis and whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability of intangible assets, other long-lived assets and, goodwill is measured by comparing their net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. Potential impairment of

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

goodwill after July 1, 2002 is being evaluated in accordance with SFAS No. 142. The SFAS No. 142 is applicable to the financial statements of the Company beginning July 1, 2002.

Revenue Recognition

Our revenue recognition policies are in compliance with Staff accounting bulletin (SAB) 101. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable,

16

BODISEN BIOTECH, INC. Management's Discussion and Analysis or Plan of Operation

the delivery is completed, no other significant obligations by us exist and collectibility is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.

Stock-based Compensation

In October 1995, the FASB issued SFAS No. 123, "Accounting for Stock-Based Compensation". SFAS No. 123 prescribes accounting and reporting standards for all stock-based compensation plans, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights. SFAS No. 123 requires compensation expense to be recorded (i) using the new fair value method or (ii) using the existing accounting rules prescribed by Accounting Principles Board Opinion No. 25, "Accounting for stock issued to employees" (APB 25) and related interpretations with proforma disclosure of what net income and earnings per share would have been had we adopted the new fair value method. We use the intrinsic value method prescribed by APB 25 and have opted for the disclosure provisions of SFAS No. 123.

Income Taxes

We utilize SFAS No. 109, "Accounting for Income Taxes," which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

According to the Provisional Regulations of the People's Republic of China on Income Tax, our Document of Reductions and Exemptions of Income Tax have been approved by the local tax bureau and the Management Regulation of Yang Ling Agricultural High-Tech Industries Demonstration Zone. As a result, we were exempted from income tax in our first two years of operations which ended March 31, 2005.

Foreign Currency Transactions and Comprehensive Income (Loss)

Accounting principles generally require that recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

section of the balance sheet. Such items, along with net income, are components of comprehensive income. Our transactions occur in Chinese Renminbi, in units of Yuan.

Recent Accounting Pronouncements

17

BODISEN BIOTECH, INC. Management's Discussion and Analysis or Plan of Operation

On May 15 2003, the FASB issued FASB Statement No. 150 ("SFAS 150"), Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity. SFAS 150 changes the accounting for certain financial instruments that, under previous guidance, could be classified as equity or "mezzanine" equity, by now requiring those instruments to be classified as liabilities (or assets in some circumstances) in the statement of financial position. Further, SFAS 150 requires disclosure regarding the terms of those instruments and settlement alternatives. SFAS 150 affects an entity's classification of the following freestanding instruments: (a) Mandatorily redeemable instruments, (b) Financial instruments to repurchase an entity's own equity instruments, (c) Financial instruments embodying obligations that the issuer must or could choose to settle by issuing a variable number of its shares or other equity instruments based solely on (i) a fixed monetary amount known at inception or (ii) something other than changes in its own equity instruments, and (d) SFAS 150 does not apply to features embedded in a financial instrument that is not a derivative in its entirety. The guidance in SFAS 150 is generally effective for all financial instruments entered into or modified after May 31, 2003, and is otherwise effective at the beginning of the first interim period beginning after June 15, 2003. For private companies, mandatorily redeemable financial instruments are subject to the provisions of SFAS 150 for the fiscal period beginning after December 15, 2003. The Company does not expect the adoption of SFAS No. 150 to have a material impact on its financial position or results of operations or cash flows.

In December 2003, the Financial Accounting Standards Board (FASB) issued a revised Interpretation No. 46, "Consolidation of Variable Interest Entities" (FIN 46R). FIN 46R addresses consolidation by business enterprises of variable interest entities and significantly changes the consolidation application of consolidation policies to variable interest entities and, thus improves comparability between enterprises engaged in similar activities when those activities are conducted through variable interest entities. The Company does not hold any variable interest entities.

Three Months Ended March 31, 2005 Compared To Three Months Ended March 31, 2004

Revenue. For the three month period ended March 31, 2005 as compared to the three month period ended March 31, 2004, the Company generated net revenues of \$4,701,675 and \$2,186,089, respectively, reflecting an increase of \$2,515,586 or 115%. The increase in revenues was primarily attributable to increased marketing efforts, which resulted in an increase in our customer base and related volume of recurring and new customer sales.

Gross Profit. The Company achieved a gross profit of \$1,654,178 for the three months ended March 31, 2005, an increase of \$781,393 or 90%, compared to \$872,785 for the three months ended March 31, 2004. Gross margin, as a percentage of revenues, decreased from 40% for the three months ended March 31, 2004, to 35% for the three months ended March 31, 2005. The decrease in gross margin is primarily attributable to an increase in sales of lower margin fertilizer products.

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

Operating expenses. The Company incurred operating expenses of \$426,610 for the three months ended March 31, 2005, an increase of \$76,550 or 22%, compared to \$350,060 for the three months ended March 31, 2004. This increase is a direct result of net revenue in March 31, 2005 being 215% of the net revenue for the

18

BODISEN BIOTECH, INC.

Management's Discussion and Analysis or Plan of Operation

same period in 2004. Aggregated selling expenses of \$148,140 accounted for expenses related to costs associated with sales and marketing of the Company's products. Operating expenses included general and administrative expenses of \$278,470 for the first quarter 2005 which related to the cost of maintaining the company's facilities, salaries and research and development.

Net Income. The Company's net income was \$796,733 for the three months ended March 31, 2005, an increase of \$375,759 or 89% compared to \$420,974 for the three months ended March 31, 2004. The increase is attributed to the substantial growth in the demand for the Company's products throughout China. The net income reflects a one-time charge of \$416,703 associated with the aggregate fair value of the warrants which were issued in connection with the \$3 million convertible financing which we completed on March 16, 2005. The net income would have been \$1,213,436 in the absence of this one-time charge, reflecting the substantial increase in the demand for our products in the markets in which we operate.

Liquidity and Capital Resources

As of March 31, 2005 the Company had \$2,793,132 cash and cash equivalents, and we believe that our current cash needs for the next twelve months can be met from working capital. The Company had net cash outflows from operations of \$2,406,046 for the three month period ended March 31, 2005 as compared to net cash outflows from operations of \$228,288 for the three month period ended March 31, 2004. The decrease in net cash flows from operations in the current period as compared to the corresponding period last year, was mainly due to an increase in the account receivables, which resulted in the usage of cash of \$2,892,853. The increase in receivables is due to the increase in sales.

Cashflows from investing activities resulted in net usage of \$890,633 in the current period as compared to net usage of \$314,822 in the corresponding period last year. The greater usage in the current period was mainly due to an increase of investment in property and equipment of \$890,633 in the three month period ended March 31, 2005 as compared to \$72,822 in the corresponding period last year.

Cashflows from financing activities in the current period resulted in a net increase in cash of \$3,968,000 compared to no financing activities in the corresponding period last year. The increase in cash from financing activities is primarily due to the proceeds raised from the \$3 million convertible debentures and warrants issued on March 16, 2005.

The Company had a net increase in cash and cash equivalents of \$671,321 in the current period as compared to a net decrease of \$495,556 in the corresponding period last year.

The majority of the Company's revenues and expenses were denominated primarily in Renminbi, the currency of the People's Republic of China. There is no assurance that exchange rates between the Renminbi and the U.S. dollar will remain stable. A revaluation of the Renminbi relative to the U.S. dollar could

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

adversely affect our business, financial condition and results of operations. We do not engage in currency hedging. Inflation has not had a material impact on our business.

19

Item 3. Controls and Procedures

The Company's Chief Executive Officer and Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures as defined in Exchange Act Rule 13a-15(e) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of the end of the period covered by this report. There were no significant changes in internal controls over financial reporting that occurred during the first quarter of 2005 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K.

(a) Exhibits:

- 3.1 Certificate of Incorporation of the Company
- 3.2 Amendment to Certificate of Incorporation of the Company, changing name to Bodisen Biotech, Inc. 3.3 By-Laws of the of the Company
- 4.1 Form of Debenture issued March 16, 2005
- 10.1 Loan Agreement, dated as of September 28, 2003, between the Company and Xianyang City Commercial Bank
- 10.2 Bodisen Biotech, Inc. 2004 Stock Option Plan
- 10.3 Form of Bodisen Biotech, Inc. Nonstatutory Stock Option Agreement
- 10.4 Securities Subscription Agreement dated March 16, 2005 between the Company and Amulet Limited
- 10.5 Registration Rights Agreement dated March 16, 2005 between the Company and Amulet Limited
- 10.6 Form of Common Stock Warrant issued March 16, 2005
- 31.1 Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a)
- 31.2 Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a)
- 32.1 Certification of the Chief Executive Officer and the Chief Financial Officer pursuant 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

20

Edgar Filing: BODISEN BIOTECH, INC - Form 10QSB

10.1	Loan Agreement, dated as of September 28, 2003, between the Company and Xianyang City Commercial Bank	Filed as Exhibit 10.2 report on Form 10-KSB Commission on March 30
10.2	Bodisen Biotech, Inc. 2004 Stock Option Plan	Filed as Exhibit 10.2 report on Form 10-KSB Commission on March 31
10.3	Form of Bodisen Biotech, Inc. Nonstatutory Stock Option Agreement	Filed as Exhibit 10.3 report on Form 10-KSB Commission on March 31
10.4	Securities Subscription Agreement dated March 16, 2005 between the Company and Amulet Limited	File as Exhibit 10.4 t statement on Form SB-2 Commission on April 22
10.5	Registration Rights Agreement dated March 16, 2005 between the Company and Amulet Limited	Filed as Exhibit 10.5 statement on Form SB-2 Commission on April 22
10.6	Form of Common Stock Warrant issued March 16, 2005	Filed as Exhibit 10.6 statement on Form SB-2 Commission on April 22
31.1	Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a)	Filed herewith as Exhi
31.2	Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a)	Filed herewith as Exhi
32.1	Certification of the Chief Executive Officer and the Chief Financial Officer pursuant 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith as Exhi